TY - JOUR T1 - Single center blind testing of a US multi-center validated diagnostic algorithm for Kawasaki disease in Asia JF - medRxiv DO - 10.1101/2022.05.12.22275028 SP - 2022.05.12.22275028 AU - Ho-Chang Kuo AU - Shiying Hao AU - Bo Jin AU - C. James Chou AU - Zhi Han AU - Ling-Sai Chang AU - Ying-Hsien Huang AU - KuoYuan Hwa AU - John C. Whitin AU - Karl G. Sylvester AU - Charitha D. Reddy AU - Henry Chubb AU - Scott R. Ceresnak AU - John T. Kanegaye AU - Adriana H. Tremoulet AU - Jane C. Burns AU - Doff McElhinney AU - Harvey J. Cohen AU - Xuefeng B. Ling Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/13/2022.05.12.22275028.abstract N2 - Kawasaki disease (KD) is the leading cause of acquired heart disease in children. A key objective of research in KD is to reduce the risk of long-term cardiovascular sequelae by expediting timely diagnosis. The major challenge in KD diagnosis is that it shares clinical signs with other childhood febrile illnesses. Our previously single-center developed computer-based two-step algorithm was further tested by a five-center validation in US. This first blinded multi-center trial validated our approach, with sufficient sensitivity and positive predictive value, to identify most patients with KD diagnosed at centers across the US.We sought to determine if our algorithmic approach applied to an Asian cohort. This study involved 418 KD and 259 febrile controls (FC) from the Chang Gung Memorial Hospital in Taiwan. Our diagnostic algorithm retained sensitivity (379 of 418; 90.7%), specificity (223 of 259; 86.1%), PPV (379 of 409; 92.7%), and NPV (223 of 247; 90.3%) comparable to previous US 2016 single center and US 2020 fiver center results. Only 4.7% (15 of 418) of KD and 2.3% (6 of 259) of FC patients were identified as indeterminate. The algorithm identified 18 of 50 (36%) KD patients who presented 2 or 3 principal criteria. Of 418 KD patients, 157 were infants younger than one year and 89.2% (140 of 157) were classified correctly. Of the 44 patients with KD who had coronary artery abnormalities, our diagnostic algorithm correctly identified 43 (97.7%) including all patients with dilated coronary artery but one who found to resolve in 8 weeks.We assessed the performance of our KD diagnostic algorithm with a single center Asian cohort. This work demonstrates the applicability of our algorithmic approach and diagnostic portability, providing evidence to support the launch of an adequately powered, multicenter study for future Asian application in the emergency department setting. If deployed in Asia, our tool promises a cost-effective diagnostic approach to allow the timely management of Asian KD patients even in the absence of KD experts, to potentially enhance the outcome for KD patients and reduce the risk of coronary artery aneurysms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the following grants CPRPG8H0051-2, CMRPG8L0011 and CMRPG8L1241 provided by Chang Gung Memorial Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards of the Chang Gung Memorial Hospital. The study was approved by the institutional review boards of Stanford University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding authorsKDKawasaki diseaseIVIGIntravenous ImmunoglobulinAHAAmerican Heart AssociationLDALinear discriminant analysisWBCWhite blood cellCRPC-reactive proteinGGTGamma glutamyl transferaseRCARight coronary arteryLADLeft anterior descendingPPVPositive predictive valueNPVNegative positive value ER -